ArticleAnnals of the rheumatic diseases2006
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2006.
Article in Annals of the rheumatic diseases, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 157 citations in OpenAlex.
- Optimal dosage and route of administration of methotrexate in rheumatoid arthritis: a systematic review of the literature.Annals of the rheumatic diseases · 2009Pooled it
- Efficacy, safety and patient-reported outcomes of combination etanercept and sulfasalazine versus etanercept alone in patients with rheumatoid arthritis: a double-blind randomised 2-year study.Annals of the rheumatic diseases · 2009Trial
- Improvements in clinical response between 12 and 24 weeks in patients with rheumatoid arthritis on etanercept therapy with or without methotrexate.Annals of the rheumatic diseases · 2008Trial
- The human anti-IL-1 beta monoclonal antibody ACZ885 is effective in joint inflammation models in mice and in a proof-of-concept study in patients with rheumatoid arthritis.Arthritis research & therapy · 2008Trial
- A Toolbox of Potential Immune-Related Therapies for Inflammatory Cardiomyopathy.Journal of cardiovascular translational research · 2021Review
- Antiphospholipid antibodies during 6-month treatment with infliximab: a preliminary report.Medical science monitor : international medical journal of experimental and clinical research · 2014Article
- Steroids Decrease Prevalence of Positive Tuberculin Skin Test in Rheumatoid Arthritis: Implications on Anti-TNF Therapies.Interdisciplinary perspectives on infectious diseases · 2014Article
- ELISPOT-IFN-gamma assay instead of tuberculin skin test for detecting latent Mycobacterium tuberculosis infection in rheumatic patients candidate to anti-TNF-alpha treatment.Clinical rheumatology · 2010Article
- Listeria endocarditis in a patient with psoriatic arthritis on infliximab: are biologic agents as treatment for inflammatory arthritis increasing the incidence of Listeria infections?The Journal of infection · 2010Review
- Prevalence of positive ppd in a cohort of rheumatoid arthritis patients.Rheumatology international · 2010Article
- The use of tumour necrosis factor alpha-blockers in daily routine. An Austrian consensus project.Clinical rheumatology · 2010Article
- Prefilled certolizumab pegol (Cimzia(®)) syringes for self-use in the treatment of rheumatoid arthritis.Medical devices (Auckland, N.Z.) · 2010Article
- Protein biochip array technology to monitor rituximab in rheumatoid arthritis.Clinical and experimental immunology · 2009Article
- Baseline comorbidities in a population-based cohort of rheumatoid arthritis patients receiving biological therapy: data from the Australian rheumatology association database.International journal of rheumatology · 2009Article
- Protein biochip array technology for cytokine profiling predicts etanercept responsiveness in rheumatoid arthritis.Clinical and experimental immunology · 2008Article
- Protective effect of an extract from Ascaris suum in experimental arthritis models.Infection and immunity · 2008Article
- TNFalpha blockade in human diseases: an overview of efficacy and safety.Clinical immunology (Orlando, Fla.) · 2008Review
- Mechanisms modulating inflammatory osteolysis: a review with insights into therapeutic targets.Pathology, research and practice · 2008Review
- Do rheumatoid arthritis patients in clinical practice benefit from switching from infliximab to a second tumor necrosis factor alpha inhibitor?Annals of the rheumatic diseases · 2007Article
- Interleukin-1 receptor antagonist delivered directly and by gene therapy inhibits matrix degradation in the intact degenerate human intervertebral disc: an in situ zymographic and gene therapy study.Arthritis research & therapy · 2007Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 11 institutions in 6 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.